another nice one.
Yahoo Finance 12/8/13
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia U.S. Food and Drug Administration Approves Gileadâ€™s Sovaldiâ„¢ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
I'm not at ASH13 but judging by flood of tweets, $GILD appears a weekend winner
Do the DD.
Wall Street Journal
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application?
Acadia said the FDA agreed the company had enough compelling data for pimavanserin, its lead drug candidate proposed for treating for Parkinson’s disease psychosis.The FDA usually requires at least twosuccessful late-stage trials, but will accept a single trial under certain circumstances, such as a drug that satisfies an unmet medical need
Seeking Alpha - By: Brian Nichols
Article :Pimavanserin: The Most Underestimated Blockbuster In Biotechnology
The current market potential for pima simply does not reflect the valuation of the PDP indication let alone ADP and Schizo. Therefore, unprecedented gains are likely. And for those of you hoping for a buyout or a substantial partnership, I'd cross your fingers and pray that management does not yet entertain such offers. Due to the disruptive nature of pima, many leading pharmaceutical companies are going to lose billions because of pima, which means Acadia is likely already speaking with or is being assessed by a handful of large companies. As peak sales estimate rise, you will see that any price under $50 is cheap, and that interest from big pharma will only intensify.
Article : Strong Comps Indicate Catalyst Pharmaceutical Partners Outstanding Value Proposition
By: Charlie Bucks
Firdapse is a strong contender for approval for several reasons. First, Firdapse has already been approved in the EU and is now selling in Europe. Second, the European Federation of Neurological Societies recommends Firdapse™ as First-Line Treatment for LEMS
lock and loaded here.